A PHASE I TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF THE UBI HIV-1MN PND PEPTIDE IMMUNOGEN, GIVEN BY IM INJECTION, IN COMBINATION WITH THE UBI MICROPARTICULATE MONOVALENT HIV-1 MN BRANCHED PEPTIDE GIVEN ORALLY, IN HIV-1 UNINFECTED VOLUNTEERS.: